Trial Suggests PRP May Delay Knee Replacement for Severe Osteoarthritis

A randomized trial in patients already scheduled for knee replacement found that platelet-rich plasma eased pain and improved function for severe osteoarthritis, without showing cartilage regrowth. Dr. Gurpreet Singh Padda says the finding supports PRP as a bridge therapy, not a cure, and highlights why bone-targeted injections and metabolic factors may matter in advanced disease.

Why it matters: - Patients with grade 3 and 4 knee osteoarthritis are often told replacement is the only remaining option. - The new randomized data suggest platelet-rich plasma may reduce pain enough to delay surgery for some patients already on the waiting list. - Delaying the first knee replacement can matter because an earlier surgery can create a longer-term revision problem later.

What happened: - Dr. Gurpreet Singh Padda, MD, MBA, MHP, who directs Regen.MD in St. Louis, marked World Arthritis Day with a restrained reading of recent evidence on severe knee osteoarthritis. - A randomized controlled trial published in June 2026 in the Journal of Orthopaedic Surgery and Research enrolled 90 patients with Kellgren-Lawrence grade 3 to 4 knee osteoarthritis. - All patients were already on total knee replacement waiting lists. - Patients were randomized to two platelet-rich plasma injections, betamethasone, or aceclofenac. - Pain scores in the PRP group fell from 6.2 to 3.3 on a visual analog scale. - Composite WOMAC scores improved from 49.0 to 32.5 in the PRP arm. - WOMAC scores worsened to 57.9 in the NSAID arm. - Opioid use, measured in morphine milligram equivalents, was lower in the PRP group. - No PRP patient withdrew from the trial, while six control patients moved ahead to earlier replacement.

The details: - The trial also tracked inflammatory and cartilage-turnover markers. - COMP, MMP-3, IL-6, IL-18, TNF-alpha and CGRP fell in the PRP group. - sTREM2, sRAGE and TGF-beta1 rose. - The authors framed the treatment as safe bridge therapy before arthroplasty. - The study did not claim cartilage regrowth. - The biomarker changes are consistent with quieter degradative signaling, but they do not prove new cartilage was built. - The trial did not include an imaging endpoint designed to test structural repair. - Dr. Padda said, "The authors called it a bridge. I would rather report a bridge accurately than a cure badly."

Between the lines: - The PRP result is narrower than many regenerative medicine claims, but that may make it more credible. - In advanced osteoarthritis, symptom relief can still be clinically meaningful even when structural reversal is not shown. - A joint-space injection may miss bone marrow lesions, which sit beneath the cartilage and track closely with pain. - Dr. Padda said, "The lesion is in the bone. We keep injecting the space next to it and calling the result disappointing." - Regen.MD says it performs intraosseous and subchondral PRP alongside intra-articular and tendon injections under fluoroscopic guidance. - The practice says that approach is aimed at the joint that still hurts after a technically correct intra-articular injection. - Dr. Padda argues osteoarthritis is not only mechanical wear. - Adipose tissue secretes leptin and adiponectin, both of which appear in synovial fluid at levels that correlate with disease severity. - Leptin promotes matrix metalloproteinase expression in chondrocytes, adding a metabolic driver to cartilage breakdown. - Obesity raises osteoarthritis risk in the hand as well as weight-bearing joints. - Advanced glycation end products can stiffen cartilage, tendon and ligament through non-enzymatic cross-linking. - That process is cumulative and can persist even after glycemic control improves. - Dr. Padda said, "We call it wear and tear. Then we find leptin in the joint fluid and keep using the phrase anyway."

What's next: - The waiting-list trial adds to evidence that PRP may serve as a bridge for some patients facing arthroplasty. - The biomarker findings may push more attention toward metabolic and inflammatory factors in osteoarthritis treatment. - The comparative value of intraosseous versus intra-articular injections will likely remain a live question in advanced disease. - Related reading is available in the waiting-list trial in plain terms and why joint degeneration is not only mechanical.

The bottom line: - The best recent randomized evidence supports PRP as a possible short-term bridge for severe knee osteoarthritis, not as proof of cartilage restoration.